ENDRA Life Sciences Inc.

NDRA

$6.20

+9.15%

N/A+$0.52

Healthcare

Medical - Diagnostics & Research

NASDAQ

Active Trading

ENDRA Life Sciences Inc. specializes in advancing the capabilities of clinical diagnostic ultrasound. The company's primary development is thermo-acoustic enhanced ultrasound technology, ...

Fundamental Analysis of NDRA

Key Strengths

Proprietary TAEUS® technology positioned for noninvasive diagnostic assessment, particularly liver fat measurement for NAFLD/NASH pathways

CE-marked status for Europe (per provided qualitative sources) improves initial regulatory accessibility versus companies without market authorization

Risk Factors

Chronic profitability shortfall: negative ROA/ROE and lack of meaningful earnings/margin data (loss-making with unreliable valuation multiples)

Negative free cash flow and weak operating cash-flow coverage indicated by enterprise-value to free-cash-flow being negative and cash flow ratios being unfavorable

Profitability

Net Margin0.00%

Operating Margin0.00%

Valuation

P/E Ratio-0.98x

Current Ratio7.10

Efficiency

ROE-224.80%

ROA-74.50%

Fundamental Analysis of NDRA

ENDRA Life Sciences Inc. (NASDAQ: NDRA) is a small-cap healthcare technology company focused on thermo-acoustic enhanced ultrasound (TAEUS®), a proprietary imaging approach aimed at improving diagnostic assessment—especially around fatty liver disease and related clinical decisions. The company’s core thesis is that measuring liver fat (steatosis) and related physiological parameters using TAEUS can provide earlier, more actionable detection compared with conventional ultrasound, potentially supporting clinical pathways for NAFLD/NASH. A notable qualitative datapoint is that TAEUS is described as CE-marked for sale in Europe, which partially de-risks market access outside the U.S., though ongoing adoption and reimbursement remain key variables. From a fundamentals perspective, the financial profile provided is consistent with early-stage commercialization: profitability metrics are effectively missing/0 in the dataset (margins shown as 0.0), while return metrics are deeply negative (ROA about -74.5% and ROE about -224.8%), and enterprise value multiples are also negative due to losses. This indicates the company is not yet generating sufficient earnings power, and valuation ratios like P/E are not meaningful when net income is negative. Cash-flow dynamics appear weak as free cash flow is negative and cash conversion indicators show abnormal/unstable working-capital behavior (the dataset shows cash conversion cycle as negative and several turnover metrics as 0). Balance-sheet liquidity looks comparatively strong on a ratio basis: current ratio is about 7.10 and quick ratio about 7.10, implying substantial near-term liquidity relative to current liabilities. Debt appears modest (debt-to-equity ~0.068; debt-to-assets ~0.054), reducing near-term solvency risk. However, interest coverage is effectively absent/0 in the dataset, aligning with a picture where operating losses dominate. In this context, the investment case is primarily option-like: upside depends on clinical validation translating into broader adoption, regulatory/clinical execution, and scaling of revenue. Downside is driven by continued losses, burn rate, dilution risk typical of small R&D-driven issuers, and potential delays in market acceptance. Based on the limited profitability signal and uncertain commercialization trajectory, the fundamental risk/reward skews cautious for long-term investors unless clearer revenue growth and margin expansion emerge.

Key Strengths of NDRA

Proprietary TAEUS® technology positioned for noninvasive diagnostic assessment, particularly liver fat measurement for NAFLD/NASH pathways
CE-marked status for Europe (per provided qualitative sources) improves initial regulatory accessibility versus companies without market authorization
Strong balance-sheet liquidity in the provided snapshot (current ratio ~7.1; quick ratio ~7.1), which can fund continued development/commercial efforts
Low leverage profile indicated by debt-to-equity (~0.068) and debt-to-assets (~0.054), lowering financial fragility relative to many loss-making peers
Strategic collaboration context (reported research collaboration with General Electric Company), which can support credibility, technical validation, and commercialization pathways

Risk Factors of NDRA

Chronic profitability shortfall: negative ROA/ROE and lack of meaningful earnings/margin data (loss-making with unreliable valuation multiples)
Negative free cash flow and weak operating cash-flow coverage indicated by enterprise-value to free-cash-flow being negative and cash flow ratios being unfavorable
Small scale and high execution risk: commercialization of medical imaging tech depends on clinical adoption, workflow integration, and evidence-generation
Regulatory and market acceptance uncertainty (disclosed risk factors include regulatory approvals and execution toward adoption/reimbursement)
Potential dilution risk typical for small, loss-making biotech/med-tech firms if additional capital is required to fund burn
Limited financial disclosures in the provided dataset (many margins/turnovers shown as 0 or N/A), reducing confidence in trend analysis and making forecasting difficult

Market Cap vs Revenue & Earnings

Earnings

n/a

Revenue

n/a

Market cap

$7.87M

-1.0x

P/E Ratio

0.0x

P/S Ratio

Earnings & Revenue

Last Reportedn/a

Earnings per share (EPS)n/a

Gross Margin0.00%

Net Profit Margin0.00%

Debt/Equity Ratio0.07

Profitability Bridge (Current vs YoY)

How gross, operating and net margins shifted versus last year.

Revenue / Net Income / FCF History (USD B)

Growth Signals of NDRA

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Revenue	—	—	—	—	Flat
Diluted EPS	—	—	—	—	Flat
Free Cash Flow	—	—	—	—	Flat

Profitability of NDRA

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Net Margin	—	0.00%	—	—	Flat
Operating Margin	—	0.00%	—	—	Flat
ROE	—	—	—	—	Flat

Financial Health of NDRA

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Current Ratio	—	7.103	—	—	Flat
Quick Ratio	—	7.103	—	—	Flat
Debt / Equity	—	0.068	—	—	Flat

Valuation of NDRA

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
P/E	—	11.10x	—	—	Flat
P/B	—	1.12x	—	—	Flat

Supply Chain of NDRA

RELATIONS

Upstream

StarFish MedicalBlatek Industries, Inc.Elite RF, LLCCriTech Research, Inc.GE HealthCare Technologies Inc.NASDAQ:GEHC Celestica Inc.NYSE:CLSOmnica Corporation

Downstream

GE HealthCare Technologies Inc.NASDAQ:GEHCQuang Phat Technology Science Equipment Co. LtdKing's College Hospital NHS Foundation TrustLMU University Hospital Munich (Klinikum der Universität München)Shanghai General HospitalCIMTEC (Centre for Imaging Technology Commercialization)

Proxies

GE HealthCare Technologies Inc.NASDAQ:GEHC Celestica Inc.NYSE:CLS Butterfly Network, Inc.NYSE:BFLY

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer